drugset / Trial / NCT05306080
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
Timeline
- Start
- 2022-04-17
- Primary completion
- 2028-01
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tadekinig alfa | Protein / enzyme biologic | 2 mg/kg | Subcutaneous |